Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289830 · ClinicalTrials.gov registry record · Phase 2
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05289830: Clinical Trial Phase 2 study, sponsored by Case Comprehensive Cancer Center.
NCT05289830 is a Phase 2 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05289830, a Phase 2 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.
Primary Outcome
Rate of depression will be measured using the Quick Inventory of Depressive Symptoms (QIDS) survey. This survey has 16 questions that are specific to the symptomatology of depression. Answers are given in the form of a four-point Likert scale ranging from 0-3, with zero relating to a standard sense of well-being and three correlating to the greatest feelings of depression. The survey is divided into 9 domains, and the survey is scored by adding the highest score on any one of the questions in ea
Interventions
- OTHER Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2023-08-27 |
| Phase | Phase 2 |
Why NCT05289830 stopped before completion
NCT05289830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05289830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05289830 about?
NCT05289830 is a clinical study titled "Escitalopram to Placebo in Patients With Localized Pancreatic Cancer". Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.
What is the current status of trial NCT05289830?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2022-08-05. Estimated completion is 2023-08-27.
What interventions are being tested in trial NCT05289830?
The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT05289830?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05289830's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI